Assessing the Feasibility of the Patient-Reported Outcomes Based Model for Community Care of Patients With Axial Spondyloarthritis Via a Type 1 Pilot Hybrid Effectiveness-Implementation Trial Using the RE-AIM Framework
Launched by SINGAPORE GENERAL HOSPITAL · May 5, 2025
Trial Information
Current as of July 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking to improve care for patients with axial spondyloarthritis, a type of arthritis that affects the spine. The main goal is to see if a new way of monitoring patients' health, called PROMs (Patient-Reported Outcomes Measures), can help doctors better understand how well their patients are doing and manage their care more effectively. The researchers want to find out what challenges there might be in using this approach, whether it can successfully postpone some appointments for stable patients, and how patients feel about it.
To participate, individuals must be at least 21 years old, have been diagnosed with axial spondyloarthritis, and have received care at Singapore General Hospital for at least six months. Participants will be randomly assigned to either receive the new PROMs-based care, which involves filling out health questionnaires every four months via text message, or to continue with regular care. If their condition is stable, their follow-up appointments may be postponed by four months, but they will still need to see their doctor at least once a year. This trial is not yet recruiting, so there is no need to apply just yet.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • diagnosed with axial spondyloarthritis according to the 2009 ASAS Classification Criteria of AxSpA
- • has been receiving care in Singapore General Hospital for at least 6 months
- • aged 21 years and above
- Exclusion Criteria:
- • Bath Ankylosing Spondylitis Disease Activity Index score of \>4
About Singapore General Hospital
Singapore General Hospital (SGH) is a leading academic medical center in Singapore, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent clinical trial sponsor, SGH plays a pivotal role in conducting cutting-edge studies that aim to improve patient outcomes and enhance medical knowledge across various specialties. With a strong focus on collaboration and multidisciplinary approaches, SGH leverages its extensive resources and expertise to facilitate rigorous clinical trials, ensuring the highest standards of safety and efficacy in the development of new treatments and therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Singapore, , Singapore
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported